233 related articles for article (PubMed ID: 16098249)
21. Capecitabine: effective oral fluoropyrimidine chemotherapy.
McKendrick J; Coutsouvelis J
Expert Opin Pharmacother; 2005 Jun; 6(7):1231-9. PubMed ID: 15957975
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
[TBL] [Abstract][Full Text] [Related]
23. Oral capecitabine: bridging the Atlantic divide in colon cancer treatment.
Van Cutsem E; Verslype C; Tejpar S
Semin Oncol; 2005 Feb; 32(1):43-51. PubMed ID: 15726505
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine plus oxaliplatin for the treatment of colorectal cancer.
Carrato A; Gallego-Plazas J; Guillén-Ponce C
Expert Rev Anticancer Ther; 2008 Feb; 8(2):161-74. PubMed ID: 18279056
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer.
McGavin JK; Goa KL
Drugs; 2001; 61(15):2309-26. PubMed ID: 11772141
[TBL] [Abstract][Full Text] [Related]
26. Feasibility and efficacy of capecitabine and FOLFIRI in patients aged 65 years and older with advanced colorectal cancer: a retrospective analysis.
Stec R; Bodnar L; Szczylik C
J Cancer Res Clin Oncol; 2010 Feb; 136(2):283-92. PubMed ID: 19693536
[TBL] [Abstract][Full Text] [Related]
27. On prejudice and facts and choices.
Köhne CH; Folprecht G
Ann Oncol; 2006 Feb; 17(2):185-7. PubMed ID: 16428244
[No Abstract] [Full Text] [Related]
28. Answering patients' needs: oral alternatives to intravenous therapy.
Borner M; Scheithauer W; Twelves C; Maroun J; Wilke H
Oncologist; 2001; 6 Suppl 4():12-6. PubMed ID: 11585969
[TBL] [Abstract][Full Text] [Related]
29. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
30. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
31. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer?
Twelves CJ; Cassidy J
Br J Cancer; 2002 Jun; 86(11):1670-6. PubMed ID: 12087448
[TBL] [Abstract][Full Text] [Related]
32. Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
Cartwright T; McCollum D; Boehm KA
Am J Clin Oncol; 2010 Jun; 33(3):307-13. PubMed ID: 20375835
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
[TBL] [Abstract][Full Text] [Related]
34. Evolution of capecitabine dosing in colorectal cancer.
Sun W
Clin Colorectal Cancer; 2010 Jan; 9(1):31-9. PubMed ID: 20100686
[TBL] [Abstract][Full Text] [Related]
35. Oral fluoropyrimidines in colorectal cancer: a door open to the future?
Delaunoit T; Neczyporenko F; Hendlisz A; Eisendrath P; Bleiberg H
Acta Gastroenterol Belg; 2004; 67(4):331-3. PubMed ID: 15727077
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence.
Comella P; Casaretti R; Sandomenico C; Avallone A; Franco L
Drugs; 2008; 68(7):949-61. PubMed ID: 18457461
[TBL] [Abstract][Full Text] [Related]
37. Health-related quality of life and cost comparison of adjuvant capecitabine versus 5-fluorouracil/leucovorin in stage III colorectal cancer patients.
Chen HH; Chen WT; Lee HC; Lin JK; Fang CY; Chou YH; Lin PC; Lin BW; Huang CC; Yeh CH; Hsu HH; Chen HC; Ting WC; Yang MC; Tan EC
Qual Life Res; 2015 Feb; 24(2):473-84. PubMed ID: 25099199
[TBL] [Abstract][Full Text] [Related]
38. Severe sequence-specific toxicity when capecitabine is given after Fluorouracil and leucovorin.
Hennig IM; Naik JD; Brown S; Szubert A; Anthoney DA; Jackson DP; Melcher AM; Crawford SM; Bradley C; Brown JM; Seymour MT
J Clin Oncol; 2008 Jul; 26(20):3411-7. PubMed ID: 18612156
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials.
Arkenau HT; Arnold D; Cassidy J; Diaz-Rubio E; Douillard JY; Hochster H; Martoni A; Grothey A; Hinke A; Schmiegel W; Schmoll HJ; Porschen R
J Clin Oncol; 2008 Dec; 26(36):5910-7. PubMed ID: 19018087
[TBL] [Abstract][Full Text] [Related]
40. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
Montagnani F; Chiriatti A; Licitra S; Aliberti C; Fiorentini G
Clin Colorectal Cancer; 2010 Oct; 9(4):243-7. PubMed ID: 20920997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]